3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management

BCACP Exam Anchor: Heart failure pharmacotherapy represents one of the highest-yield topics on the BCACP examination. Mastery requires deep familiarity with the 2022 AHA/ACC/HFSA Guideline recommendations: rapid quadruple therapy initiation in HFrEF, precise laboratory safety thresholds for MRAs and ARNIs, pharmacokinetic washout intervals, evidence-based beta-blocker selection, and evolving SGLT2 inhibitor indications across all ejection fraction phenotypes.

---

Heart Failure Phenotypes & Staging Systems

The 2022 AHA/ACC/HFSA guidelines classify heart failure based on left ventricular ejection fraction (LVEF), which dictates specific disease-modifying therapeutic strategies:

• HFrEF (Heart Failure with reduced Ejection Fraction): $\text{LVEF} \le 40%$. Characterized by progressive ventricular dilation and eccentric remodeling. Benefit from all four foundational GDMT pillars.
• HFmrEF (Heart Failure with mildly reduced Ejection Fraction): $\text{LVEF } 41%\text{ to } 49%$. SGLT2 inhibitors hold a Class 1/2a recommendation; ARNIs, ACEis/ARBs, and MRAs have Class 2b evidence.
• HFpEF (Heart Failure with preserved Ejection Fraction): $\text{LVEF} \ge 50%$. SGLT2 inhibitors carry a Class 1/2a recommendation to reduce HF hospitalizations; MRAs and ARNIs carry Class 2b/2a recommendations for selected patients.
• HFimpEF (Heart Failure with improved Ejection Fraction): Baseline $\text{LVEF} \le 40%$ with a subsequent measurement $>40%$ (at least a 10-point improvement). Critical Rule: GDMT must be continued indefinitely even if EF normalizes, as medication withdrawal results in high rates of relapse and left ventricular decompensation.

Staging vs. Functional Classification

---

The Four Pillars of GDMT in HFrEF (LVEF ≤40%)

The historical paradigm of sequential, slow medication titration over many months has been replaced by the rapid quadruple therapy sequencing model. All four pillars should be initiated simultaneously or in rapid sequence (within 4 to 6 weeks) at low doses, followed by concurrent upward titration to target doses as tolerated.

---

In-Depth Analysis of the Four Pillars

Pillar 1: Sacubitril/Valsartan (ARNI)

• Mechanism of Action: Sacubitril is a prodrug whose active metabolite (LBQ657) inhibits neprilysin (neutral endopeptidase), preventing the enzymatic degradation of beneficial endogenous vasoactive peptides including atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), adrenomedullin, and bradykinin. Valsartan selectively blocks the angiotensin II type 1 ($\text{AT}_1$) receptor, mitigating vasoconstriction, aldosterone release, and myocardial fibrosis.
• Biomarker Interpretation: Neprilysin breaks down BNP but does not degrade N-terminal pro-B-type natriuretic peptide (NT-proBNP). Therefore, BNP levels increase falsely upon starting sacubitril/valsartan; NT-proBNP is the sole reliable biomarker for assessing clinical congestion and treatment response in patients on an ARNI.
• The 36-Hour Washout Rule: Both ACE inhibitors and neprilysin degrade bradykinin. Dual simultaneous inhibition leads to massive bradykinin accumulation and life-threatening angioedema. When switching from an ACE inhibitor to sacubitril/valsartan, clinicians must withhold the ACE inhibitor for a minimum of 36 hours prior to the first ARNI dose. Switching from an ARB to an ARNI carries no bradykinin duplication risk, so no washout interval is required (the next scheduled dose can be sacubitril/valsartan).
• Initiation & Titration:
  • Standard dose switch (from enalapril $\ge 10\text{ mg/day}$ or lisinopril $\ge 10\text{ mg/day}$): Start 49/51 mg PO BID (sacubitril 49 mg / valsartan 51 mg).
  • Low-dose switch (from low-dose ACEi/ARB, ACEi/ARB-naive, or $\text{eGFR} < 30\text{ mL/min/1.73m}^2$): Start 24/26 mg PO BID.
  • Double the dose every 2 to 4 weeks to achieve the target of 97/103 mg PO BID.
• Contraindications: Prior history of angioedema (hereditary, idiopathic, or related to ACEi/ARB), concomitant aliskiren in patients with diabetes, and pregnancy (teratogenic).

Pillar 2: Evidence-Based Beta-Blockers

• The Three Proven Agents: Only carvedilol, metoprolol succinate extended-release, and bisoprolol have demonstrated significant reductions in total mortality, sudden cardiac death, and hospitalization in major randomized controlled trials. Immediate-release metoprolol tartrate, atenolol, and propranolol do not have proven mortality benefit in HFrEF and represent unacceptable prescribing errors.
• Clinical Distinction:
  • Carvedilol: Non-selective $\beta_1/\beta_2$ blocker with $\alpha_1$-adrenergic antagonism. Produces potent systemic vasodilation and greater blood pressure lowering than $\beta_1$-selective agents. Must be taken with food to slow absorption and minimize orthostatic hypotension. Target dose: 25 mg BID (or 50 mg BID if body weight $>85\text{ kg}$; or carvedilol phosphate CR 80 mg daily).
  • Metoprolol succinate ER: $\beta_1$-cardioselective antagonist. Preferred when baseline systolic blood pressure is borderline low or in patients with mild reactive airway disease. Target dose: 200 mg once daily.
  • Bisoprolol: $\beta_1$-selective antagonist. Target dose: 10 mg once daily.
• Initiation Prerequisites: Patients must be clinically euvolemic and stable (no overt fluid overload or acute decompensation requiring escalating IV diuretics). Beta-blockade acutely reduces inotropy; starting low and titrating slowly prevents transient worsening of congestion. If mild fluid retention occurs during titration, increase the loop diuretic dose temporarily rather than discontinuing the beta-blocker.

Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs)

• Mechanism & Benefits: Spironolactone and eplerenone block aldosterone receptors in the distal renal tubule and myocardium, preventing sodium retention, potassium/magnesium wasting, endothelial dysfunction, and myocardial interstitial fibrosis. The RALES (spironolactone) and EMPHASIS-HF (eplerenone) trials demonstrated a 30% reduction in all-cause mortality in HFrEF.
• Safety Initiation Thresholds:
  • Serum Potassium: $\le 5.0\text{ mEq/L}$
  • Renal Function: $\text{eGFR} \ge 30\text{ mL/min/1.73m}^2$ (or Serum Creatinine $\le 2.5\text{ mg/dL}$ in men, $\le 2.0\text{ mg/dL}$ in women)
• Laboratory Monitoring Protocol: Measure serum potassium and renal function at baseline, 1 to 2 weeks, 4 weeks, and every 3 to 6 months thereafter. Withhold or halve MRA therapy if serum potassium rises above $5.5\text{ mEq/L}$, and discontinue if $\text{K}^+ \ge 6.0\text{ mEq/L}$.
• Agent Comparison: Spironolactone is non-selective and interacts with androgen and progesterone receptors, causing gynecomastia, breast tenderness, and menstrual irregularities in ~10% of patients. Eplerenone is a highly selective MRA with minimal affinity for sex steroid receptors (<1% gynecomastia incidence), making it the drug of choice when spironolactone induces endocrine adverse effects.

Pillar 4: SGLT2 Inhibitors

• Cardiorenal Mechanisms: Dapagliflozin and empagliflozin inhibit sodium-glucose cotransporter-2 in the proximal renal tubule. In heart failure, their profound benefits operate independently of glycemic control through osmotic diuresis, reduction in preload/afterload, enhanced myocardial energetics (ketone oxidation), improved tubuloglomerular feedback, and attenuation of cardiac fibrosis.
• Dosing & Administration: Dapagliflozin 10 mg once daily or Empagliflozin 10 mg once daily. No titration is required. Initiation is permitted down to an eGFR of $20\text{ mL/min/1.73m}^2$ (empagliflozin) or $25\text{ mL/min/1.73m}^2$ (dapagliflozin), with continuation until dialysis initiation.
• Adverse Effects & Safety Counseling:
  • Genital mycotic infections (counsel on daily hygiene).
  • Transient decline in eGFR (up to 30% initial drop is expected due to restored tubuloglomerular feedback and does not warrant discontinuation).
  • Volume depletion / hypotension (may allow modest loop diuretic dose reduction).
  • Euglycemic Diabetic Ketoacidosis (euDKA): Instruct patients to withhold SGLT2i 3 days prior to major elective surgery or during severe acute medical illness/prolonged fasting.

---

Secondary & Add-On Pharmacotherapy in HFrEF

---

Diuretic Therapy & Decongestion Strategies

Loop diuretics are indicated in all HF patients with current or prior fluid retention to restore and maintain euvolemia. Unlike the four foundational pillars, loop diuretics do not reduce mortality, but they relieve congestion, improve functional capacity, and enable the safe uptitration of beta-blockers and ARNIs.

Loop Diuretic Equivalence & Bioavailability

Managing Diuretic Resistance

When escalating loop diuretic doses fail to achieve adequate diuresis:

1. Convert Oral Furosemide to Torsemide or Bumetanide: Overcomes impaired gastrointestinal absorption caused by splanchnic venous congestion.
2. Implement Sequential Nephron Blockade: Combine a loop diuretic (acting at the thick ascending limb of Henle) with an oral thiazide-like diuretic such as metolazone (2.5 to 5 mg PO administered 30 minutes prior to the loop diuretic) or IV chlorothiazide. Metolazone blocks compensatory distal convoluted tubule sodium reabsorption, producing profound synergistic natriuresis. Monitor electrolytes (K+, Mg+, Na+) and renal function closely to prevent severe hypokalemic metabolic alkalosis and volume collapse.

---

Management of HFpEF (LVEF ≥50%) & HFmrEF (LVEF 41–49%)

Historically, pharmacotherapy for HFpEF was limited to symptom management with diuretics. Landmark randomized trials have established evidence-based disease-modifying therapies:

1. SGLT2 Inhibitors (Class 1 / 2a): In the EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials, SGLT2 inhibition significantly reduced the primary composite outcome of cardiovascular death or heart failure hospitalization by ~18–21% in patients with $\text{LVEF} > 40%$. SGLT2 inhibitors are the first drug class to achieve definitive guideline endorsement across the entire spectrum of LVEF.
2. Mineralocorticoid Receptor Antagonists (Class 2a/2b): Spironolactone was evaluated in the TOPCAT trial; pre-specified regional analyses in the Americas showed a significant reduction in HF hospitalizations and CV mortality in symptomatic HFpEF, particularly in patients with elevated baseline BNP or LVEF at the lower end of the preserved range (45%–55%).
3. ARNI (Class 2a/2b): In the PARAGON-HF trial, sacubitril/valsartan showed a significant reduction in total HF hospitalizations in pre-specified subgroups, most notably in patients with $\text{LVEF} \le 57%$ and in females.
4. Blood Pressure & Comorbidity Control: Rigorous systolic BP control ($<130\text{ mmHg}$), rhythm control for atrial fibrillation, weight loss, and treatment of obstructive sleep apnea are vital to prevent progressive LV stiffness and diastolic dysfunction.